Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel Targeted Therapy for Precursor B-Cell Acute Lymphoblastic Leukemia: Anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugate

1 Jan 2016

Abstract excerpt

The exponential rise in molecular and genomic data has generated a vast array of therapeutic targets. Oligonucleotide-based technologies to down regulate these molecular targets have promising therapeutic efficacy. However, there is relatively limited success in translating this into effective in vivo cancer therapeutics. The primary challenge is the lack of effective cancer cell-targeted delivery methods,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to CAR-T cell therapy research
Share to Chronic Lymphocytic Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27455414
DOI: 10.2119/molmed.2015.00210

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel Targeted Therapy for Precursor B-Cell Acute Lymphoblastic Leukemia: Anti-CD22 Antibody-MXD3 Antisense Oligonucleotide ConjugatePMID 27455414Read ↗

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AMLSemantic proximity Read ↗

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199Semantic proximity Read ↗

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AMLSemantic proximity Read ↗

BCR-ABL1 molecular remission after 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle.Semantic proximity Read ↗

Selection of a novel cell-internalizing RNA aptamer specific for CD22 antigen in B cell acute lymphoblastic leukemiaSemantic proximity Read ↗

SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AMLSemantic proximity Read ↗

Novel Antisense Anti-MDM2 Mixed-Backbone Oligonucleotides: Proof of Principle, In Vitro and In Vivo Activities, and MechanismsSemantic proximity Read ↗

Streptavidin-drug conjugates streamline optimization of antibody-based conditioning for hematopoietic stem cell transplantationSemantic proximity Read ↗

A PBD dimer-containing antibody-drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.Semantic proximity Read ↗

<i>In Vivo</i> Selection of anti-glioblastoma DNA aptamer-drug conjugates in an orthotopic patient-derived xenograft modelSemantic proximity Read ↗

Antitumor activity of Z15-0-2, a bispecific nanobody targeting PD-1 and CTLA-4Semantic proximity Read ↗

Screening and Development of Constitutively Synergistic Combination Drug Formulations for T Cell Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.